News

Acrivon Therapeutics' shares climb 14% on plans to present cancer-test data

Shares of Acrivon Therapeutics ACRV, -3.26% advanced in post-market trading after the biopharmaceutical company said it would present clinical trial data in connection with a biomarker test for ovarian and endometrial cancers.

04/24/2024

Buffett Grabs More of This Stock, Plus Other Notable Insider Buying

At the end of the previous week, the Oracle of Omaha yet again boosted his stake in a media giant's tracking stocks, even with shares still in retreat.

04/21/2024

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is Acrivon Therapeutics, Inc. Common Stock (ACRV) a buy, sell, or hold?

Acrivon Therapeutics, Inc. Common Stock (ACRV) can sell. Click on Rating Page for detail.

What is Acrivon Therapeutics, Inc. Common Stock's stock price?

The price of Acrivon Therapeutics, Inc. Common Stock (ACRV) is 8.46 and it was updated on 2024-04-27 07:00:38.

Is Acrivon Therapeutics, Inc. Common Stock (ACRV) overvalued or undervalued?

Currently Acrivon Therapeutics, Inc. Common Stock (ACRV) is in undervalued.

News

From:

To:

News
ACRV Stock Jumps 55% as Acrivon Therapeutics Gets $130 Million Boost Acrivon Therapeutics (NASDAQ: ACRV ) stock is rocketing higher on Tuesday after the clinical-stage biopharmaceutical company announced a $130 million private placement. This new funding comes from a private investment in public equity (PIPE) with existing and new accredited investors. Tue, Apr. 09, 2024
What To Buy After You Sell The Russell 2000 What To Buy After You Sell The Russell 2000 Wed, Apr. 03, 2024
Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316 ACR-2316, a novel, selective dual WEE1 and PKMYT1 inhibitor development candidate, designed using AP3 to achieve superior single agent activity, demonstrates potent preclinical activity across studies Tue, Mar. 05, 2024
Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference WATERTOWN, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced the company's president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat on Tuesday, February 13, 2024 at 2:40 p.m. ET at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. Tue, Feb. 06, 2024
Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference WATERTOWN, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, today announced the company's president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat on Tuesday, November 28, 2023 at 8:30 a.m. ET at the Piper Sandler 35th Annual Healthcare Conference in New York, NY. Tue, Nov. 21, 2023

SEC Filings

SEC Filings
Acrivon Therapeutics, Inc. Common Stock (ACRV) - DEFA14A SEC Filings 04/26/2024
Acrivon Therapeutics, Inc. Common Stock (ACRV) - DEF 14A SEC Filings 04/26/2024
Acrivon Therapeutics, Inc. Common Stock (ACRV) - ARS SEC Filings 04/26/2024
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 8-K - Current report SEC Filings 04/24/2024
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 4 SEC Filings 04/19/2024
Acrivon Therapeutics, Inc. Common Stock (ACRV) - S-3 SEC Filings 04/17/2024
Acrivon Therapeutics, Inc. Common Stock (ACRV) - SC 13G/A SEC Filings 04/15/2024
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 4 SEC Filings 04/15/2024
Acrivon Therapeutics, Inc. Common Stock (ACRV) - SC 13D/A SEC Filings 04/11/2024
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 8-K - Current report SEC Filings 04/09/2024
Acrivon Therapeutics, Inc. Common Stock (ACRV) - S-8 SEC Filings 03/29/2024
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 8-K - Current report SEC Filings 03/28/2024
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 10-K - Current report SEC Filings 03/28/2024
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 4 SEC Filings 03/06/2024
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 3 SEC Filings 03/06/2024
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 8-K - Current report SEC Filings 03/04/2024
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 4 SEC Filings 02/16/2024
Acrivon Therapeutics, Inc. Common Stock (ACRV) - SC 13G/A SEC Filings 02/14/2024
Acrivon Therapeutics, Inc. Common Stock (ACRV) - SC 13G/A SEC Filings 02/13/2024
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 4 SEC Filings 02/09/2024
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 3 SEC Filings 02/09/2024
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 8-K - Current report SEC Filings 02/08/2024
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 4 SEC Filings 01/19/2024
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 4 SEC Filings 01/16/2024
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 3 SEC Filings 01/12/2024
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 8-K - Current report SEC Filings 01/08/2024
Acrivon Therapeutics, Inc. Common Stock (ACRV) - EFFECT SEC Filings 12/18/2023
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 8-K - Current report SEC Filings 12/08/2023
Acrivon Therapeutics, Inc. Common Stock (ACRV) - S-3 SEC Filings 12/01/2023
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 4 SEC Filings 11/16/2023
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 8-K - Current report SEC Filings 11/09/2023
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 10-Q - Quarterly Report SEC Filings 11/09/2023
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 4 SEC Filings 10/19/2023
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 4 SEC Filings 09/28/2023
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 3 SEC Filings 09/28/2023
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 8-K - Current report SEC Filings 09/05/2023
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 4 SEC Filings 08/23/2023
Acrivon Therapeutics, Inc. Common Stock (ACRV) - S-8 SEC Filings 08/11/2023
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 8-K - Current report SEC Filings 08/11/2023
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 10-Q - Quarterly Report SEC Filings 08/11/2023
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 4 SEC Filings 06/28/2023
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 3 SEC Filings 06/28/2023
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 8-K - Current report SEC Filings 06/22/2023
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 4 SEC Filings 06/20/2023
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 4 SEC Filings 06/14/2023
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 4 SEC Filings 06/06/2023
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 8-K - Current report SEC Filings 06/05/2023
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 4 SEC Filings 06/01/2023
Acrivon Therapeutics, Inc. Common Stock (ACRV) - DEFR14A SEC Filings 05/30/2023
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 8-K - Current report SEC Filings 05/09/2023
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 10-Q - Quarterly Report SEC Filings 05/09/2023
Acrivon Therapeutics, Inc. Common Stock (ACRV) - DEFA14A SEC Filings 05/01/2023
Acrivon Therapeutics, Inc. Common Stock (ACRV) - DEF 14A SEC Filings 05/01/2023
Acrivon Therapeutics, Inc. Common Stock (ACRV) - ARS SEC Filings 05/01/2023
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 8-K - Current report SEC Filings 05/01/2023
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 8-K - Current report SEC Filings 04/25/2023
Acrivon Therapeutics, Inc. Common Stock (ACRV) - SC 13D/A SEC Filings 03/30/2023
Acrivon Therapeutics, Inc. Common Stock (ACRV) - S-8 SEC Filings 03/29/2023
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 8-K - Current report SEC Filings 03/28/2023
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 10-K - Current report SEC Filings 03/28/2023
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 8-K - Current report SEC Filings 03/13/2023
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 8-K - Current report SEC Filings 03/03/2023
Acrivon Therapeutics, Inc. Common Stock (ACRV) - SC 13G/A SEC Filings 02/14/2023
Acrivon Therapeutics, Inc. Common Stock (ACRV) - SC 13G SEC Filings 02/14/2023
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 10-Q - Quarterly Report SEC Filings 12/15/2022
Acrivon Therapeutics, Inc. Common Stock (ACRV) - SC 13G SEC Filings 11/28/2022
Acrivon Therapeutics, Inc. Common Stock (ACRV) - SC 13D SEC Filings 11/28/2022
Acrivon Therapeutics, Inc. Common Stock (ACRV) - SC 13G SEC Filings 11/25/2022
Acrivon Therapeutics, Inc. Common Stock (ACRV) - SC 13G SEC Filings 11/21/2022
Acrivon Therapeutics, Inc. Common Stock (ACRV) - SC 13G SEC Filings 11/18/2022
Acrivon Therapeutics, Inc. Common Stock (ACRV) - S-8 SEC Filings 11/17/2022
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 8-K - Current report SEC Filings 11/17/2022
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 424B4 SEC Filings 11/16/2022
Acrivon Therapeutics, Inc. Common Stock (ACRV) - S-1MEF SEC Filings 11/14/2022
Acrivon Therapeutics, Inc. Common Stock (ACRV) - FWP SEC Filings 11/14/2022
Acrivon Therapeutics, Inc. Common Stock (ACRV) - EFFECT SEC Filings 11/10/2022
Acrivon Therapeutics, Inc. Common Stock (ACRV) - SEC STAFF LETTER SEC Filings 11/09/2022
Acrivon Therapeutics, Inc. Common Stock (ACRV) - S-1/A SEC Filings 11/08/2022
Acrivon Therapeutics, Inc. Common Stock (ACRV) - CERT SEC Filings 11/08/2022
Acrivon Therapeutics, Inc. Common Stock (ACRV) - CORRESP SEC Filings 11/07/2022
Acrivon Therapeutics, Inc. Common Stock (ACRV) - 8-A12B SEC Filings 11/07/2022
Acrivon Therapeutics, Inc. Common Stock (ACRV) - S-1/A SEC Filings 11/03/2022
Acrivon Therapeutics, Inc. Common Stock (ACRV) - S-1 SEC Filings 10/17/2022
Acrivon Therapeutics, Inc. Common Stock (ACRV) - CORRESP SEC Filings 10/17/2022
Acrivon Therapeutics, Inc. Common Stock (ACRV) - UPLOAD SEC Filings 10/05/2022
Acrivon Therapeutics, Inc. Common Stock (ACRV) - DRSLTR SEC Filings 09/22/2022
Acrivon Therapeutics, Inc. Common Stock (ACRV) - DRS/A SEC Filings 09/22/2022
Acrivon Therapeutics, Inc. Common Stock (ACRV) - SEC STAFF LETTER SEC Filings 09/14/2022
Acrivon Therapeutics, Inc. Common Stock (ACRV) - UPLOAD SEC Filings 09/12/2022
Acrivon Therapeutics, Inc. Common Stock (ACRV) - DRS SEC Filings 08/12/2022
Acrivon Therapeutics, Inc. Common Stock (ACRV) - D SEC Filings 11/23/2021
Acrivon Therapeutics, Inc. Common Stock (ACRV) - D SEC Filings 02/12/2021

Press Releases

StockPrice Release
Acrivon therapeutics reports initial positive clinical data for acr-368 and pipeline program progress today at corporate r&d event 04/24/2024
Acrivon therapeutics to host corporate r&d event highlighting ap3 and pipeline progress, including ongoing prospective validation of acr-368 oncosignature with initial phase 2 data for acr-368, and preclinical progress for acr-2316 04/16/2024
Acrivon therapeutics presents data at aacr annual meeting highlighting the capabilities of acrivon predictive precision proteomics (ap3) for the discovery of acr-2316, a novel, selective wee1/pkmyt1 inhibitor, and the identification of actionable resistance mechanisms to acr-368 04/10/2024
Acrivon therapeutics announces $130 million private placement financing 04/09/2024
Acrivon therapeutics reports fourth quarter and full year 2023 financial results and business highlights 03/28/2024
Acrivon therapeutics to present data at aacr annual meeting demonstrating power of acrivon predictive precision proteomics (ap3) platform and its internally-discovered, potent wee1/pkmyt1 development candidate, acr-2316 03/05/2024
Acrivon therapeutics to participate in a panel discussion at the td cowen 44th annual health care conference 02/27/2024
Acrivon therapeutics to present at the oppenheimer 34th annual healthcare life sciences conference 02/06/2024
Acrivon therapeutics announces inducement grants under nasdaq listing rule 5635(c)(4) 01/12/2024
Acrivon therapeutics to present at the piper sandler annual healthcare conference 11/21/2023
Acrivon therapeutics announces inducement grant under nasdaq listing rule 5635(c)(4) 11/21/2023
Acrivon therapeutics reports third quarter 2023 financial results and business highlights 11/09/2023
Acrivon therapeutics presents data demonstrating capabilities of its ap3 platform and acr-368 oncosignature assay for patient responder identification at the aacr-nci-eortc international conference on molecular targets and cancer therapeutics 10/16/2023
Acrivon therapeutics announces inducement grants under nasdaq listing rule 5635(c)(4) 09/28/2023
Acrivon therapeutics to highlight its acr-368 oncosignature test, used in ongoing phase 2 study to treat patients based on predicted sensitivity to monotherapy with its chk1/2 inhibitor acr-368, at the upcoming aacr-nci-eortc international conference on molecular targets and cancer therapeutics 09/19/2023
Acrivon therapeutics announces acr-2316, a novel dual wee1 and pkmyt1 inhibitor development candidate, designed using acrivon's ap3 platform to achieve potent single agent activity, as demonstrated in preclinical studies 09/05/2023
Acrivon therapeutics to participate in two investor conferences in september 08/30/2023
Acrivon therapeutics announces inducement grants under nasdaq listing rule 5635(c)(4) 08/17/2023
Acrivon therapeutics reports second quarter 2023 financial results and business highlights 08/11/2023
Acrivon therapeutics announces the appointment of seasoned biopharma executive charles baum, m.d., ph.d., a recognized leader in clinical precision oncology, to its board of directors 06/22/2023
Acrivon therapeutics to present at the jefferies healthcare conference 06/02/2023
Acrivon therapeutics reports first quarter 2023 financial results and business highlights 05/09/2023
Acrivon therapeutics to present at the h.c. wainwright bioconnect investor conference 04/25/2023
Acrivon therapeutics to present at the stifel 2023 targeted oncology days conference 04/18/2023
Acrivon therapeutics reports fourth quarter and full year 2022 financial results and business highlights 03/28/2023
Acrivon therapeutics to present at the oppenheimer 33rd annual healthcare conference 03/06/2023
Acrivon therapeutics announces pricing of initial public offering 11/14/2022

More Headlines

News
Acrivon Therapeutics to Participate in Two Investor Conferences in September WATERTOWN, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today announced the company's management team will participate in two investor conferences in September. 08/30/2023
7 Up-and-Coming Stocks to Buy for the Next Decade In arguably most cases involving expert financial advice, you will encounter guidance toward established enterprises, not up-and-coming stocks to buy. While the latter category certainly dials up the heat in terms of overall sexiness, some folks just can't handle adventurous portfolios. 06/29/2023
Acrivon Therapeutics to Present at the Jefferies Healthcare Conference WATERTOWN, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today announced the company's president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat on Thursday, June 8, 2023 at 8:00 a.m. ET at the Jefferies Healthcare Conference in New York. 06/02/2023
Acrivon Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference WATERTOWN, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today announced the company's chief executive officer and president, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat on Tuesday, May 2, 2023 at 3:00 p.m. ET at the H.C. Wainwright BioConnect Investor Conference in New York. 04/25/2023
Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference WATERTOWN, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today announced the company's chief executive officer and president, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat on Tuesday, April 25, 2023 at 3:00 p.m. ET at the Stifel 2023 Targeted Oncology Days Conference taking place virtually. 04/18/2023
Acrivon: Precision-Testing Your Trial Patients Before Enrolment ACRV has a platform that tests trial patients for sensitivity to a tested drug before enrolling them. This way, it aims to make phase 2 trials more efficient. 03/26/2023
Acrivon Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference WATERTOWN, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today announced the company's chief executive officer and president, Peter Blume-Jensen, M.D., Ph.D., will present a company overview on Monday, March 13, 2023 at 3:20 p.m. ET at the Oppenheimer 33rd Annual Healthcare Conference taking place virtually. 03/06/2023
Acrivon Therapeutics sets IPO price range Acrivon Therapeutics Inc. on Thursday set an estimated price range of $16 to $18 a share in its upcoming initial public offering (IPO) on the Nasdaq under the symbol ACRV. With 5.9 million shares in the IPO, Acrivon Therapeutics will raise $100 million based on the midpoint of its estimated price range. 11/03/2022

Unlock

ACRV Ratings Summary

ACRV Quant Ranking

Is Acrivon Therapeutics, Inc. Common Stock (ACRV) a buy, sell, or hold?

What is Acrivon Therapeutics, Inc. Common Stock's stock price?

Is Acrivon Therapeutics, Inc. Common Stock (ACRV) overvalued or undervalued?

Acrivon Therapeutics to Participate in Two Investor Conferences in September

7 Up-and-Coming Stocks to Buy for the Next Decade

Acrivon Therapeutics to Present at the Jefferies Healthcare Conference

Acrivon Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference

Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference

Acrivon: Precision-Testing Your Trial Patients Before Enrolment

Acrivon Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

Acrivon Therapeutics sets IPO price range